AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17631129 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 434
Study 17631129 — intervention group
Group type: COMPARATOR
Intervention: White Light
Number of subjects: 434
Study 15728066 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive epidural analgesia
Number of subjects: 3261
Study 15728066 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive local anesthetic wound infiltration
Number of subjects: 3261
Study 15728066 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive NSAID administration
Number of subjects: 3261
Study 15728066 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic NMDA antagonist
Number of subjects: 3261
Study 15728066 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic opioid administration
Number of subjects: 3261
Study 11804984 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg per os per day
Number of subjects: 19
Study 11804984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg per os per day
Number of subjects: 19
Study 11804984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of estrogens and ramipril
Number of subjects: 19
Study 10359888 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive intervention for dust mite elimination
Number of subjects: 0
Study 10359888 — intervention group
Group type: COMPARATOR
Intervention: Standard environmental control intervention
Number of subjects: 0
Study 7677236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 0
Study 1646194 — intervention group
Group type: COMPARATOR
Intervention: Thoracic megavoltage radiotherapy alone (65 Gy in 26 fractions over 45 days)
Number of subjects: 353
Study 1646194 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic megavoltage radiotherapy preceded and followed by 3 monthly cycles of VCPC (vindesine 1.5 mg/m2 d 1‐2, cyclophosphamide 200 mg/m2 d 2‐4, cisplatinum 100 mg/m2 d 2, lomustine 75 mg/m2 d 3)
Number of subjects: 353
Study 7025235 — intervention group
Group type: EXPERIMENTAL
Intervention: T-N/10 HCl perfusion
Number of subjects: 64
Study 7025235 — intervention group
Group type: COMPARATOR
Intervention: N/10 HCl perfusion
Number of subjects: 64
Study 30586700 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Anticoagulation (OAC) alone
Number of subjects: 696
Study 30586700 — intervention group
Group type: COMPARATOR
Intervention: Combined OAC and single Antiplatelet Therapy (APT)
Number of subjects: 696
Study 27475283 — intervention group
Group type: EXPERIMENTAL
Intervention: C. vulgaris (four 300 mg tablets)
Number of subjects: 70
Study 27475283 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four 300 mg tablets)
Number of subjects: 70
Study 26202179 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil therapy
Number of subjects: 0
Study 25029833 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 60
Study 25029833 — intervention group
Group type: COMPARATOR
Intervention: Control group (no transcutaneous electrical nerve stimulation)
Number of subjects: 60
Study 21909049 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV
Number of subjects: 52
Study 21909049 — intervention group
Group type: COMPARATOR
Intervention: 7vCRM
Number of subjects: 52
Study 21909049 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional PCV dose
Number of subjects: 52
Study 19651272 — intervention group
Group type: EXPERIMENTAL
Intervention: FES leg cycling exercise
Number of subjects: 30
Study 19651272 — intervention group
Group type: COMPARATOR
Intervention: Passive leg cycling
Number of subjects: 30
Study 19651272 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation therapy (noncycling control group)
Number of subjects: 30
Study 17477777 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stressors (family stressors)
Number of subjects: 101
Study 17477777 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 101
Study 17477777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower income
Number of subjects: 101
Study 17477777 — intervention group
Group type: EXPERIMENTAL
Intervention: Working at a job
Number of subjects: 101
Study 17477777 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 101
Study 16314627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose leucovorin plus fluorouracil (Mayo Clinic; LDLV) regimen for 30 to 32 weeks
Number of subjects: 3794
Study 16314627 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose leucovorin plus fluorouracil (Roswell Park; HDLV) regimen for 30 to 32 weeks
Number of subjects: 3794
Study 16314627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose leucovorin plus levamisole plus fluorouracil (LDLV plus LEV) regimen for 30 to 32 weeks
Number of subjects: 3794
Study 16314627 — intervention group
Group type: COMPARATOR
Intervention: Levamisole plus fluorouracil (LEV) for 1 year
Number of subjects: 3794
Study 16314627 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and disease-free survival across all treatment arms
Number of subjects: 3794
Study 11571954 — intervention group
Group type: EXPERIMENTAL
Intervention: Misgav Ladach procedure
Number of subjects: 160
Study 11571954 — intervention group
Group type: COMPARATOR
Intervention: Traditional CS
Number of subjects: 160
Study 9630000 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 225 mg bd
Number of subjects: 618
Study 9630000 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 150 mg tid
Number of subjects: 618
Study 9630000 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine 50 mg bd
Number of subjects: 618
Study 7875268 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 8
Study 7875268 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms)
Number of subjects: 8
Study 7875268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3345339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (orally administered)
Number of subjects: 11
Study 3345339 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated stable sickle cell subjects)
Number of subjects: 11
Study 31726472 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed and humidified carbon dioxide (W-H-CO2) insufflation
Number of subjects: 50
Study 31726472 — intervention group
Group type: COMPARATOR
Intervention: Control group (no W-H-CO2)
Number of subjects: 50
Study 28598560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet group (TG)
Number of subjects: 52
Study 28598560 — intervention group
Group type: COMPARATOR
Intervention: Non-tourniquet group (NG)
Number of subjects: 52
Study 26614142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 2.5mg hyperbaric levobupivacaine plus 12.5 μg fentanyl
Number of subjects: 52
Study 26614142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 2.5mg hyperbaric levobupivacaine plus 25 μg fentanyl
Number of subjects: 52
Study 23218892 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal‐5'‐phosphate 35 mg
Number of subjects: 214
Study 23218892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 21621169 — intervention group
Group type: COMPARATOR
Intervention: Institutional-based therapy (IT)
Number of subjects: 70
Study 21621169 — intervention group
Group type: EXPERIMENTAL
Intervention: IT plus structured home activity program (HAP)
Number of subjects: 70
Study 21621169 — intervention group
Group type: EXPERIMENTAL
Intervention: HAP
Number of subjects: 70
Study 19469703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 240
Study 19469703 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised artemether-lumefantrine (AL)
Number of subjects: 240
Study 19469703 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised artesunate-amodiaquine (ASAQ)
Number of subjects: 240
Study 16404099 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile narratives (MN)
Number of subjects: 33
Study 16404099 — intervention group
Group type: COMPARATOR
Intervention: New age music and videos (NA)
Number of subjects: 33
Study 16404099 — intervention group
Group type: COMPARATOR
Intervention: No treatment (CT)
Number of subjects: 33
Study 15547070 — intervention group
Group type: EXPERIMENTAL
Intervention: Self assessed health measure before screening
Number of subjects: 23654
Study 15547070 — intervention group
Group type: EXPERIMENTAL
Intervention: Self assessed health measure after screening
Number of subjects: 23654
Study 10836913 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human relaxin, 25 microg/kg per day
Number of subjects: 68
Study 10836913 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human relaxin, 100 microg/kg per day
Number of subjects: 68
Study 10836913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 8770972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (2 micrograms) and 3.5 mEq/liter calcium dialysate for six weeks
Number of subjects: 2
Study 8770972 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mEq/liter calcium dialysate and increased oral calcium supplementation for six weeks
Number of subjects: 2
Study 1460407 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine
Number of subjects: 0
Study 1460407 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine
Number of subjects: 0
Study 6361099 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (control group)
Number of subjects: 780
Study 6361099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy (intervention group)
Number of subjects: 780
Study 6361099 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (randomizable group)
Number of subjects: 780
Study 6361099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy (randomizable group)
Number of subjects: 780
Study 30698487 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg/mL pirfenidone solution
Number of subjects: 44
Study 30698487 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pirfenidone
Number of subjects: 44
Study 30833215 — intervention group
Group type: EXPERIMENTAL
Intervention: cathodal HD-tDCS to inhibit the vlPFC
Number of subjects: 52
Study 30833215 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 52
Study 30833215 — intervention group
Group type: EXPERIMENTAL
Intervention: cathodal HD-tDCS to inhibit the dmPFC
Number of subjects: 52
Study 28985109 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid Alpha1‐PI
Number of subjects: 32
Study 28985109 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized Alpha1‐PI
Number of subjects: 32
Study 25892175 — intervention group
Group type: EXPERIMENTAL
Intervention: RELATE with Couple CARE (RCC)
Number of subjects: 301
Study 25892175 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple Coping Enhancement Training (CCET)
Number of subjects: 301
Study 25892175 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 301
Study 23688180 — intervention group
Group type: COMPARATOR
Intervention: SB + PA (combined sedentary behavior and physical activity intervention)
Number of subjects: 293
Study 23688180 — intervention group
Group type: COMPARATOR
Intervention: SB (sedentary behavior intervention)
Number of subjects: 293
Study 23688180 — intervention group
Group type: COMPARATOR
Intervention: All intervention groups (SB, PA, SB + PA)
Number of subjects: 293
Study 21560124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutorial teaching orientation strategies at specific stages of laparoscopic cholecystectomy
Number of subjects: 30
Study 19140204 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg/d rhIL-18
Number of subjects: 64
Study 19140204 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg/d rhIL-18
Number of subjects: 64
Study 19140204 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg/d rhIL-18
Number of subjects: 64
Study 19140204 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (0.01, 0.1, 1.0 mg/kg/d rhIL-18)
Number of subjects: 64
Study 17724555 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week rehabilitation programme in a warm climate
Number of subjects: 60
Study 15121266 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose midazolam with propofol (0.03 mg/kg midazolam + 0.7 mg/kg bolus propofol + 2 mg/kg/h propofol infusion)
Number of subjects: 30
Study 15121266 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (0.7 mg/kg bolus propofol + 2 mg/kg/h propofol infusion)
Number of subjects: 30
Study 12427437 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of intravenous glucagon
Number of subjects: 40
Study 12427437 — intervention group
Group type: COMPARATOR
Intervention: No intravenous glucagon (Control)
Number of subjects: 40
Study 10075343 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g oligofructose/d
Number of subjects: 12
Study 10075343 — intervention group
Group type: COMPARATOR
Intervention: sucrose (control treatment)
Number of subjects: 12
Study 7559195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam hexetil (CTM) 200 mg bd for 5 days
Number of subjects: 250
Study 7559195 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (PEV) 1 megaunit (600 mg) tds for 10 days
Number of subjects: 250
Study 7559195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam hexetil (CTM)
Number of subjects: 250
Study 7559195 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (PEV)
Number of subjects: 250
Study 1958992 — intervention group
Group type: EXPERIMENTAL
Intervention: Choledochoscopy
Number of subjects: 157
Study 1958992 — intervention group
Group type: COMPARATOR
Intervention: Control group (no choledochoscopy)
Number of subjects: 157
Study 7003391 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol alone
Number of subjects: 0
Study 7003391 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol plus clofibrate
Number of subjects: 0
Study 7003391 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol plus niacin
Number of subjects: 0
Study 6381000 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation-H
Number of subjects: 12
Study 6381000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30097422 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioral therapy (guided ICBT)
Number of subjects: 258
Study 30097422 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 258
Study 27385750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 1456
Study 27385750 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Number of subjects: 1456
Study 27385750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1456
Study 27385750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held dynamometry (HHD)
Number of subjects: 1456
Study 27385750 — intervention group
Group type: EXPERIMENTAL
Intervention: ALSFRS-R
Number of subjects: 1456
Study 27385750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital capacity
Number of subjects: 1456
Study 24962637 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with LOC eating
Number of subjects: 80
Study 24962637 — intervention group
Group type: COMPARATOR
Intervention: Individuals without LOC eating
Number of subjects: 80
Study 20456255 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin UV A corneal collagen cross-linking (CXL)
Number of subjects: 44
Study 21098406 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST), 4 weeks, 5 days per week, 20 minutes per day
Number of subjects: 60
Study 21098406 — intervention group
Group type: COMPARATOR
Intervention: Sham control group
Number of subjects: 60
Study 18482817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/d)
Number of subjects: 127
Study 18482817 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine (200 mg/d)
Number of subjects: 127
Study 15966376 — intervention group
Group type: EXPERIMENTAL
Intervention: landiolol 125 microg x kg(‐1) x min(‐1) for one minute followed by 40 microg x kg(‐1) x min(‐1)
Number of subjects: 40
Study 15966376 — intervention group
Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 40
Study 15966376 — intervention group
Group type: EXPERIMENTAL
Intervention: landiolol
Number of subjects: 40
Study 12927226 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg/day)
Number of subjects: 25
Study 12927226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10975959 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic
Number of subjects: 13
Study 10975959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8762419 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Mianyi Granule (YQMYG)
Number of subjects: 72
Study 8762419 — intervention group
Group type: COMPARATOR
Intervention: Zhenqi Fuzheng Granule (ZQFZG)
Number of subjects: 72
Study 1987848 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomosis ring (BAR)
Number of subjects: 782
Study 6340015 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 percent bupivacaine 1/200,000 epinephrine
Number of subjects: 32
Study 6340015 — intervention group
Group type: COMPARATOR
Intervention: 2 percent lidocaine 1/100,000 epinephrine
Number of subjects: 32
Study 31825895 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 1329
Study 31825895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1329
Study 29709070 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Bio‐Electro‐Magnetic‐Energy‐Regulation (BEMER) device
Number of subjects: 108
Study 29709070 — intervention group
Group type: COMPARATOR
Intervention: Inactive device (sham treatment)
Number of subjects: 108
Study 27921992 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorrhoidal artery ligation (HAL)
Number of subjects: 370
Study 27921992 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation (RBL)
Number of subjects: 370
Study 25102685 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs for clearing heat and promoting diuresis (n = 126)
Number of subjects: 186
Study 25102685 — intervention group
Group type: COMPARATOR
Intervention: Western Medicine (n = 60)
Number of subjects: 186
Study 22906218 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion in a Computer Supported Collaborative Learning (CSCL) environment
Number of subjects: 47
Study 22906218 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised papers
Number of subjects: 47
Study 22906218 — intervention group
Group type: COMPARATOR
Intervention: Unrevised papers
Number of subjects: 47
Study 20708062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular 2‐implant overdentures (IODs)
Number of subjects: 214
Study 20708062 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures (CDs)
Number of subjects: 214
Study 17420340 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous Biventricular (BiV) pacing
Number of subjects: 306
Study 17420340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Biventricular (BiV) pacing
Number of subjects: 306
Study 17420340 — intervention group
Group type: COMPARATOR
Intervention: Left Ventricular (LV) pacing
Number of subjects: 306
Study 17420340 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Simultaneous BiV, Sequential BiV, LV pacing)
Number of subjects: 306
Study 15746297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal phenoxybenzamine
Number of subjects: 9
Study 15746297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11978254 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed prescription
Number of subjects: 129
Study 11978254 — intervention group
Group type: COMPARATOR
Intervention: Immediate prescription
Number of subjects: 129
Study 9639218 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg intravenous dexamethasone over 36 hours
Number of subjects: 30
Study 9639218 — intervention group
Group type: COMPARATOR
Intervention: No steroid medication (control group)
Number of subjects: 30
Study 8033493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous torsemide
Number of subjects: 0
Study 8033493 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral torsemide
Number of subjects: 0
Study 8033493 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide (both intravenous and oral)
Number of subjects: 0
Study 8033493 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 0
Study 2466880 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (20 mg every 8 hours for 48 hours)
Number of subjects: 20
Study 2466880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2466880 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal antigen challenge
Number of subjects: 20
Study 2466880 — intervention group
Group type: COMPARATOR
Intervention: Nonatopic subjects
Number of subjects: 20
Study 1234498 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (‐‐)‐tryptophan (5 g)
Number of subjects: 0
Study 31157566 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated bolus calculator (ABC) (Accu‐Check Aviva Expert)
Number of subjects: 65
Study 31157566 — intervention group
Group type: COMPARATOR
Intervention: Manual insulin calculations (control)
Number of subjects: 65
Study 27531024 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week telephone-delivered exercise intervention from peer volunteers
Number of subjects: 76
Study 27531024 — intervention group
Group type: COMPARATOR
Intervention: Contact control condition
Number of subjects: 76
Study 25884936 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted partner notification services at intervention sites
Number of subjects: 1080
Study 25884936 — intervention group
Group type: COMPARATOR
Intervention: Passive partner referral at control sites
Number of subjects: 1080
Study 23611105 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory and Aging Program (n = 21)
Number of subjects: 42
Study 23611105 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n = 21)
Number of subjects: 42
Study 21292168 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5 mg once daily
Number of subjects: 485